
|Articles|March 5, 2008
DermTech adds Allan C. Halpern, M.D., to company's melanoma advisory board
Biotechnology company DermTech announced the addition of Allan C. Halpern, M.D., chief of dermatology at Memorial Sloan-Kettering Cancer Center, to its melanoma advisory board, according to The Earth Times.
Advertisement
La Jolla, Calif.
- Biotechnology company DermTech announced the addition of Allan C. Halpern, M.D., chief of dermatology at Memorial Sloan-Kettering Cancer Center, to its melanoma advisory board, according to The Earth Times.
DermTech is developing molecular diagnostics for the early detection of melanoma and other diseases. Dr. Halpern is a widely recognized expert in the early detection and management of melanoma in high-risk patients, the Times reports.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
CSU With Biochemical C1 Inhibitor Deficiency: Case Report Raises Diagnostic Questions
2
Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases
3
Common Mistakes in Managing Hair Loss and Pigmentary Disorders
4
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
5











